nih

In fiscal year 2021, the nationwide success rate of applicants for National Institutes of Health (NIH) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase I awards decreased slightly from FY 2020. This continued a downward trend over recent years. The success rate for NIH SBIR/STTR Phase I was nearly 13 percent (647 of 5,132 approved) in FY 2021, a decrease from nearly 14 percent (636 of 4,684 approved) in FY 2020 and from nearly 16 percent for all proposals submitted over the past decade.

With a $1 billion investment over the next three years, Advanced Research Projects Agency for Health (ARPA-H) will be a standalone agency within the National Institutes of Health (NIH) and is designed to produce quicker research outcomes.

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs of the National Institutes of Health (NIH) supported the development of 99 drugs from 1996-2020 — a total that includes 16 percent of all such treatments that made a “significant” advance over available medicines.

The National Science and Technology Council (NSTC) has released a new request for information (RFI) related to a national strategic plan for advanced manufacturing, and the National Institutes of Health (NIH) are seeking information on how the scientific community uses public data tools. Both RFIs provide an opportunity for the tech-based economic development field to shape the future of federal innovation policy. 

As the global economy continues to struggle through the COVID-19 pandemic, the National Institutes of Health (NIH) has released an interactive online tool for discovering success stories of small business innovation and entrepreneurship. Showcasing several of the businesses that have successfully leveraged NIH small business funding — totaling more than $1 billion annually — to develop healthcare products and services, NIH’s Small Business Education and Entrepreneurial Development (SEED) office hopes that the tool will inspire others to start businesses and develop their technologies.

The NIH’s High-Risk, High-Reward Research program (HRHR) has the potential to overturn fundamental paradigms, but historically the applicant and awardee pools have not fully represented the demographic and geographic diversity across the U.S. biomedical workforce, says the NIH’s deputy director for extramural research.

The most recently-passed federal legislation to address COVID-19 included funding for the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA) to accelerate testing. The provision, added by Sens.

In this week’s edition of Useful Stats, we take a look at NIH’s SBIR/STTR program by state, including the success rate of applications, the share SBIR awards make up of NIH funding to for-profit companies by state, and the total number of awards by state. It should be noted that SSTI was able to prepare this information because of the excellent transparency of information that NIH offers on its website, a model that should be replicated by other federal agencies.

For the first time and in response to the COVID-19 outbreak, the National Institute of Allergy and Infectious Diseases (NIAID) together with the National Institute of General Medical Sciences (NIGMS) has activated the NIH Urgent Award mechanism. The targeted opportunity is intended to provide funds for NIH grantees applying to expand the scope of their active grant.

NIH has taken an expanded approach in defining scientists from disadvantaged backgrounds, in an effort to encourage and enable more biomedical scientists. NIH determined that the criteria they were using in defining disadvantaged was too narrow; for example, what was considered low-income ($25,750 for a family of four) is actually considered severe poverty and represents an overly strict threshold, the reviewers found.